Progress in multimodality therapy for primary hepatocellular carcinoma unsuitable for surgery

WEN Xiao; LI Yuxin; LIU Jia; YANG Hongru

您当前的位置：

首页 >

文章列表页 >

Progress in multimodality therapy for primary hepatocellular carcinoma unsuitable for surgery

更新时间：2023-04-14

- Progress in multimodality therapy for primary hepatocellular carcinoma unsuitable for surgery
- Journal of Southwest Medical University Vol. 43, Issue 4, Pages: 416-420(2020)
- 作者机构：
  
  1. 西南医科大学
  2. 泸州市人民医院肿瘤科
- 作者简介：
- 基金信息：
- DOI：
  CLC： R735.7
- Published：2020，
扫描看全文
[1]温霄,李雨馨,刘佳,杨红茹.不适合手术的原发性肝癌的综合治疗进展[J].西南医科大学学报,2020,43(04):416-420.

WEN Xiao, LI Yuxin, LIU Jia, et al. Progress in multimodality therapy for primary hepatocellular carcinoma unsuitable for surgery. [J]. Journal of Southwest Medical University 43(4):416-420(2020)
[1]温霄,李雨馨,刘佳,杨红茹.不适合手术的原发性肝癌的综合治疗进展[J].西南医科大学学报,2020,43(04):416-420. DOI：

WEN Xiao, LI Yuxin, LIU Jia, et al. Progress in multimodality therapy for primary hepatocellular carcinoma unsuitable for surgery. [J]. Journal of Southwest Medical University 43(4):416-420(2020) DOI：

摘要

目前手术切除仍然是治疗原发性肝癌的首选

但由于早期肝癌缺乏典型临床表现

一旦出现症状和体征疾病多已进入中晚期

手术治疗效果不佳

对于此部分病人采用介入、消融、靶向、免疫、放化疗等综合治疗。本文参考相关资料

探讨不适合手术的原发性肝癌的综合治疗进展。

Abstract

At present

surgical resection is still the first choice for the treatment of primary hepatocellular carcinoma. However

due to the lack of typical clinical manifestations in early hepatocellular carcinoma

most cases have entered the advanced stage once symptoms and signs appear

which results in a poor surgical outcome. For these patients

multimodality therapy including interventional therapy

ablation therapy

targeted therapy

immunotherapy

and radiochemotherapy is adopted. With reference to relevant data

this article reviews the progress in multimodality therapy for primary hepatocellular carcinoma that is unsuitable for surgery.

关键词

原发性肝癌介入治疗消融治疗靶向治疗免疫治疗

Keywords

Hepatocellular CarcinomaTranscatheter arterial chemoembolizationAblationTargeted therapyImmunotherapy

references

查看原文

Views

379

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research progress of CAR-T cell immunotherapy in solid tumors

Progress of chimeric antigen receptor T cell immunotherapy in refractory/relapse hematologic malignancies

Research on natural biomimetic nano-drug delivery system for treatment of rheumatoid arthritis

Value of bevacizumab in the first-line treatment of epithelial ovarian cancer in the era of precision medicine

Research advances in hepatocellular carcinoma immunotherapy

Related Author

JIA Yiwei

FENG Cong

SUN Shiyu

MA Xingcong

ZHANG Shuqun

WANG Xiaman

YANG Yun

HE Aili

Related Institution

Department of Oncology，The Second Affiliated Hospital of Xi'an Jiaotong University

Department of Hematology, the Second Affiliated Hospital of Medical College of Xi'an Jiaotong University

Department of Pharmaceutical Sciences，School of Pharmacy，Southwest Medical University

School of Biomedical Engineering，Sichuan University

Department of Obstetrics and Gynecology，West China Second Hospital，Sichuan University

⁰